

11 - References

References

Prescribing in hepatic and renal impairment CHAPTER 8 References

1. Slim M, et al. Hepatic safety of atypical antipsychotics: current evidence and future directions. *Drug Saf* 2016; 39:925–943.
2. Todorović Vukotić N, et al. Antidepressants- and antipsychotics-induced hepatotoxicity. *Arch Toxicol* 2021; 95:767–789.
3. Marwick KF, et al. Antipsychotics and abnormal liver function tests: systematic review. *Clin Neuropharmacol* 2012; 35:244–253.
4. Morlán-Coarasa MJ, et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. *Psychopharmacology (Berl)* 2016; 233:3947–3952.
5. Baeza I, et al. One-year prospective study of liver function tests in children and adolescents on second-generation antipsychotics: is there a link with metabolic syndrome? *J Child Adolesc Psychopharmacol* 2018; 28:463–473.
6. Datapharm Communications Ltd. *Electronic Medicines Compendium*. 2023; <https://www.medicines.org.uk/emc>.
7. IBM Watson Health. *IBM Micromedex Solutions*. 2024; <https://www.ibm.com/watson-health/about/micromedex>.
8. Zeiss R, et al. Drug-associated liver injury related to antipsychotics: exploratory analysis of pharmacovigilance data. *J Clin Psychopharmacol* 2022; 42:440–444.
9. Nikogosyan G, et al. Acute aripiprazole-associated liver injury. *J Clin Psychopharmacol* 2021; 41:344–346.
10. Mallikaarjun S, et al. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. *Clin Pharmacokinet* 2008; 47:533–542.
11. Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer 'atypical' antipsychotics: Part 3. Effects of renal and hepatic impairment. *J Psychiatr Pract* 2012; 18:430–437.
12. Chico G, et al. Clinical vignettes 482 aripiprazole causes cholelithiasis and hepatitis: a rare finding. *Am J Gastroenterol* 2005; 100:S164.
13. Kornischka J, et al. Acute drug-induced hepatitis during aripiprazole monotherapy: a case report. *J Pharmacovigil* 2016; 4:1000201.
14. Castanheira L, et al. Aripiprazole-induced hepatitis: a case report. *Clin Psychopharmacol Neurosci* 2019; 17:551–555.

15. Peeters P, et al. Asenapine pharmacokinetics in hepatic and renal impairment. *Clin Pharmacokinet* 2011; 50:471-481.
16. Schultz K, et al. A case of pseudo-Stauffer's syndrome related to asenapine use. *Schizophr Res* 2015; 169:500-501.
17. Parikh NB, et al. Clinical role of brexpiprazole in depression and schizophrenia. *Ther Clin Risk Manag* 2017; 13:299-306.
18. Cutler AJ, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. *CNS Spectr* 2018; 23:39-50.
19. Brown CA, et al. Clozapine toxicity and hepatitis. *J Clin Psychopharmacol* 2013; 33:570-571.
20. Tucker P. Liver toxicity with clozapine. *Aust NZ J Psychiatry* 2013; 47:975-976.
21. Gaertner HJ, et al. Side effects of clozapine. *Psychopharmacology (Berl)* 1989; 99 Suppl:S97-100.
22. Lally J, et al. Hepatitis, interstitial nephritis, and pancreatitis in association with clozapine treatment: a systematic review of case series and reports. *J Clin Psychopharmacol* 2018; 38:520-527.
23. Takács A, et al. Clozapine rechallenge in a patient with clozapine-induced hepatitis. *Australas Psychiatry* 2019; 27:535.
24. Amdisen A, et al. Zuclophenthixol acetate in viscoleo - a new drug formulation. An open Nordic multicentre study of zuclophenthixol acetate in Viscoleo in patients with acute psychoses including mania and exacerbation of chronic psychoses. *Acta Psychiatr Scand* 1987; 75:99-107.
25. Wistedt B, et al. Zuclophenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. *Acta Psychiatr Scand* 1991; 84:14-21.
26. Demuth N, et al. [Flupentixol-induced acute hepatitis]. *Gastroenterol Clin Biol* 1999; 23:152-153.
27. Nolen WA, et al. Disturbances of liver function of long acting neuroleptic drugs. *Pharmakopsychiatr Neuropsychopharmakol* 1978; 11:199-204.
28. LiverTox. Clinical and Research Information on Drug-induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
29. Vanda Pharmaceuticals Inc. FANAPT® (iloperidone) tablets 1mg, 2mg, 4mg, 6mg, 8mg, 10mg, 12mg indication and important safety information. 2021; <http://www.fanapt.com/product/pi/pdf/fanapt.pdf>.
30. US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. 2023; <https://www.accessdata.fda.gov/scripts/cder/daf>.
31. Greenwood J, et al. Lumateperone: a novel antipsychotic for schizophrenia. *Ann Pharmacother* 2021; 55:98-104.
32. Druschky K, et al. Severe drug-induced liver injury in patients under treatment with antipsychotic drugs: data from the AMSP study. *World J Biol Psychiatry* 2021; 22:373-386.
33. Gunther M, et al. Antipsychotic safety in liver disease: a narrative review and practical guide for the clinician. *J Acad Consult Liaison Psychiatry* 2023; 64:73-82.
34. Amatniek J, et al. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease. *Clin Schizophr Relat Psychoses* 2014; 8:8-20.

35. Macaluso M, et al. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder. *Expert Opin Drug Metab Toxicol* 2017; 13:871–879.
36. Chang CH, et al. Paliperidone is associated with reduced risk of severe hepatic outcome in patients with schizophrenia and viral hepatitis: a nationwide population-based cohort study. *Psychiatry Res* 2019; 281:112597.
37. Vats A, et al. Treatment of patients with schizophrenia and comorbid chronic hepatitis with paliperidone: a systematic review. *Cureus* 2023; 15:e34234.
38. Braude MR, et al. Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools. *Hepatol Int* 2021; 15:812–820.
39. Khorassani F, et al. Risperidone- and paliperidone-induced hepatotoxicity: case report and review of literature. *Am J Health Syst Pharm* 2020; 77:1578–1584.
40. Das A, et al. Liver injury associated with quetiapine: an illustrative case report. *J Clin Psychopharmacol* 2017; 37:623–625.

764 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 8

41. Ko S, et al. Investigation of hepatic adverse events due to quetiapine by using the common data model. *Pharmacoepidemiol Drug Saf* 2023; 32:1341–1349.
42. Monnelly EP, et al. Quetiapine for treatment of alcohol dependence. *J Clin Psychopharmacol* 2004; 24:532–535.
43. Brown ES, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. *Alcohol Clin Exp Res* 2014; 38:2113–2118.
44. Vatsalya V, et al. Safety assessment of liver injury with quetiapine fumarate XR management in very heavy drinking alcohol-dependent patients. *Clin Drug Investig* 2016; 36:935–944.
45. Holtmann M, et al. Risperidone-associated steatohepatitis and excessive weight-gain. *Pharmacopsychiatry* 2003; 36:206–207.
46. Voican CS, et al. Antidepressant-induced liver injury: a review for clinicians. *Am J Psychiatry* 2014; 171:404–415.
47. Freiesleben SD, et al. A systematic review of agomelatine--induced liver injury. *J Mol Psychiatry* 2015; 3:4.
48. Gahr M, et al. Safety and tolerability of agomelatine: focus on hepatotoxicity. *Curr Drug Metab* 2014; 15:694–702.
49. Billioti de Gage S, et al. Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the French National Health Insurance Database. *CNS Drugs* 2018; 32:673–684.
50. Pladevall-Vila M, et al. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. *CNS Drugs* 2019; 33:383–395.
51. Lundbeck Limited. Summary of product characteristics. Citalopram 20mg film-coated tablets. 2023; <https://www.medicines.org.uk/emc/product/992/smpc>.
52. Lopez-Torres E, et al. Hepatotoxicity related to citalopram (Letter). *Am J Psychiatry* 2004; 161:923–924.
53. Hanje AJ, et al. Case report: fulminant hepatic failure involving duloxetine hydrochloride. *Clin Gastroenterol Hepatol* 2006; 4:912–917.
54. Vuppalanchi R, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. *Aliment Pharmacol Ther* 2010; 32:1174–1183.
55. Lin ND, et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. *BMC Gastroenterol* 2015; 15:134.
56. McIntyre RS, et al. The hepatic safety profile of duloxetine: a review. *Expert Opin Drug Metab Toxicol* 2008; 4:281–285.
57. Bunchorntavakul C, et al. Drug hepatotoxicity: newer agents. *Clin Liver Dis* 2017; 21:115–134.
58. Lundbeck Limited. Summary of product characteristics. Escitalopram 10mg film-coated tablets. 2023; <https://www.medicines.org.uk/emc/product/7718/smpc>.
59. Rao N. The clinical pharmacokinetics of escitalopram. *Clin Pharmacokinet* 2007; 46:281–290.
60. Schenker S, et al. Fluoxetine disposition and elimination in cirrhosis. *Clin*

Pharmacol Ther 1988; 44:353–359. 61. Cai Q, et al. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999; 74:692–694. 62. FriedenberG FK, et al. Hepatitis secondary to fluoxetine treatment. Am J Psychiatry 1996; 153:580. 63. Johnston DE, et al. Chronic hepatitis related to use of fluoxetine. Am J Gastroenterol 1997; 92:1225–1226. 64. Hale AS. New antidepressants: use in high-risk patients. J Clin Psychiatry 1993; 54 Suppl:61–70. 65. Mylan. Summary of product characteristics. Fluvoxamine 100mg film-coated tablets. 2023; <https://www.medicines.org.uk/emc/-product/6603/smpc>. 66. Stoeckel K, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand Suppl 1990; 360:94–97. 67. Mylan Specialty LP. Highlights of prescribing information. EMSAM® (selegiline transdermal system) 2014; https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021336s005s010,021708s000lbl.pdf. 68. Thomas E, et al. Mirtazapine--induced steatosis. Int J Clin Pharmacol Ther 2017; 55:630–632. 69. Shaheen AA, et al. The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. PLoS One 2018; 13:e0194839. 70. Sandoz Limited. Summary of product characteristics. Paroxetine 20mg tablets. 2024; <https://www.medicines.org.uk/emc/product/4168/smpc>. 71. Colakoglu O, et al. Toxic hepatitis associated with paroxetine. Int J Clin Pract 2005; 59:861–862. 72. Düll MM, et al. Evaluation and management of pruritus in primary biliary cholangitis. Clin Liver Dis 2022; 26:727–745. 73. Tran A, et al. Pharmacokinetics of reboxetine in volunteers with hepatic impairment. Clin Drug Investig 2000; 19:473–477. 74. Mylan. Summary of product characteristics. Setraline 100mg tablets. 2023; <https://www.medicines.org.uk/emc/product/10586/smpc>. 75. Committee on Safety of Medicines. Lofepamine (Gamanil) and abnormal blood tests of liver function. Curr Problems 1988; 23:371. 76. Archer DF, et al. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause 2013; 20:47–56. 77. Baird-Bellaire S, et al. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Clin Ther 2013; 35:782–794. 78. Ryan PB, et al. Atypical antipsychotics and the risks of acute kidney injury and related outcomes among older adults: a replication analysis and an evaluation of adapted confounding control strategies. Drugs Aging 2017; 34:211–219. 79. Chen G, et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2018; 57:673–686. 80. Bjornsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008; 118:281–290. 81. Guo HL, et al. Valproic acid and the liver injury in patients with epilepsy: an update. Curr Pharm Des 2019; 25:343–351. 82. Panei P, et al. Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. Adv Drug Reaction Bull 2010; 260:999–1002. 83. Reed VA, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs 2016; 30:603–628.

Prescribing in hepatic and renal impairment CHAPTER 8 84. Shire Pharmaceuticals Limited. Summary of product characteristics. Elvanse 20mg, 30mg, 40mg, 50mg, 60mg, 70mg hard capsules. 2023; <https://www.medicines.org.uk/emc/search?q=%22Elvanse%22>. 85. Medice UK Ltd. Summary of product characteristics. Amfexa 5mg, 10mg, 20mg tablets. 2023; <https://www.medicines.org.uk/emc/search?q=amfexa>. 86. Vanga RR, et al. Adderall induced acute liver injury: a rare case and review of the literature. Case Rep Gastrointest Med 2013; 2013:902892. 87. Hood B, et al. Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD. Pediatrics 2010; 125:e1510–1513. 88. Tong HY, et al. Liver transplant in a patient under methylphenidate therapy: a case report and review of the literature. Case Rep Pediatr 2015; 2015:437298. 89. Flynn Pharma Ltd. Summary of product characteristics.

Circadin 2mg prolonged-release tablets. 2021; <https://www.medicines.org.uk/emc/product/2809/smpc>. 90. SANOFI. Summary of product characteristics. Zimovane 7.5mg and 3.75mg LS film-coated tablets. 2023; <https://www.medicines.org.uk/emc/product/2855/smpc>. 91. Zentiva. Summary of product characteristics. Zolpidem tartrate 5mg, 10mg tablets. 2021; <https://www.medicines.org.uk/emc/search?q=zolpidem>. 92. Gunja N. The clinical and forensic toxicology of Z-drugs. *J Med Toxicol* 2013; 9:155–162. 93. Wu T, et al. Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease. *Medicine (Baltimore)* 2021; 100:e26243. 94. Jackson CD, et al. Hold the gaba: a case of gabapentin-induced hepatotoxicity. *Cureus* 2018; 10:e2269. 95. Chahal J, et al. Gabapentin-induced liver toxicity. *Am J Ther* 2022; 29:e751–e752. 96. Kärppä M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. *Sleep* 2020; 43:zsaa123. 97. Upjohn UK Limited. Summary of product characteristics. Lyrica (pregabalin) 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules. 2024; <https://www.medicines.org.uk/emc/product/10303/smpc>. 98. Sendra JM, et al. Pregabalin-induced hepatotoxicity. *Ann Pharmacother* 2011; 45:e32. 99. Düzenli T, et al. Pregabalin as a rare cause of hepatotoxicity. *Pain Med* 2017; 18:1407–1408. 100. Grattagliano I, et al. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. *World J Gastroenterol* 2009; 15:4865–4876. 101. Rosalki SB, et al. Liver function profiles and their interpretation. *Br J Hosp Med* 1994; 51:181–186. 102. Rettenbacher MA, et al. Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. *J Clin Psychopharmacol* 2006; 26:500–503.

Revision #1

Created 2026-01-04 20:17:20 UTC by Omar Ayman

Updated 2026-01-04 20:17:20 UTC by Omar Ayman